Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients

PURPOSE: Programmed cell death protein 1 (PD-1) inhibitor plus apatinib is reported to be a promising strategy for advanced cancers. Moreover, a PD-1 inhibitor or apatinib exerts a certain efficacy in advanced colorectal cancer (CRC), whereas their synergistic effect is unclear. This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Dengdeng, Liu, Dongliang, Liang, Lichuan, Shen, Tongyi, Shi, Chenzhang, Qin, Huanlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160599/
https://www.ncbi.nlm.nih.gov/pubmed/35664730
http://dx.doi.org/10.3389/fonc.2022.863392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160599/
https://www.ncbi.nlm.nih.gov/pubmed/35664730
http://dx.doi.org/10.3389/fonc.2022.863392

Ejemplares similares